Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 31 chart positions in 31 markets.
By chart position
- 🇺🇸US · Tech News#39100K to 300K
- 🇨🇦CA · Tech News#42100K to 300K
- 🇬🇧GB · Tech News#7130K to 100K
- 🇩🇪DE · Tech News#1105K to 30K
- 🇦🇺AU · Tech News#1575K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
161K to 512K🎙 Daily cadence·64 episodes·Last published today - Monthly Reach
Unique listeners across all episodes (30 days)
536K to 1.7M🇺🇸18%🇨🇦18%🇰🇷18%+28 more - Active Followers
Loyal subscribers who consistently listen
214K to 682K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 38 epsHosts
Recent guests
No guests detected in recent episodes.
Recent episodes
Carsgen's $2T Satricabtagene Approval Milestone | Pharma and Biotech Daily
Jun 24, 2026
5m 14s
Carsgen's CAR-T Breakthrough in China for Solid Tumors | Pharma and Biotech Daily
Jun 23, 2026
4m 39s
FDA Approves Alzheimer's Drug Amid Debate | Pharma and Biotech Daily
Jun 22, 2026
4m 14s
FDA Approves Utebzi, Biogen Acquires Raythera for $1B | Pharma and Biotech Daily
Jun 19, 2026
4m 51s
Eli Lilly's $65B M&A Surge & FDA's Drug Import Approval | Pharma and Biotech Daily
Jun 18, 2026
5m 19s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/24/26 | Carsgen's $2T Satricabtagene Approval Milestone | Pharma and Biotech Daily | Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into the latest scientific breakthroughs, regulatory advancements, and strategic industry movements that are shaping the landscape of healthcare innovation. Kicking off with significant strides in drug approvals, Carsgen Therapeutics has marked a major milestone with the approval of satricabtagene autoleucel by China's National Medical Prod... | 5m 14s | ||||||
| 6/23/26 | Carsgen's CAR-T Breakthrough in China for Solid Tumors | Pharma and Biotech Daily | Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of groundbreaking advancements and strategic shifts that are shaping the future of healthcare. In a remarkable development from China, Carsgen has achieved approval for the world's first CAR-T therapy targeting solid tumors. This therapy focuses on Claudin18.2, marking an unprecedented expansion of CAR-T applications beyond hematolo... | 4m 39s | ||||||
| 6/22/26 | FDA Approves Alzheimer's Drug Amid Debate | Pharma and Biotech Daily | Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most exciting stories shaping the industry right now. Let's start with a groundbreaking advancement in gene therapy. Researchers have achieved a significant milestone by successfully using CRISPR technology to treat a rare genetic disorder in humans. This marks one of the first times that CRISPR has been applied directly to ... | 4m 14s | ||||||
| 6/19/26 | FDA Approves Utebzi, Biogen Acquires Raythera for $1B | Pharma and Biotech Daily | Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to evolve, with significant scientific advancements, regulatory updates, and strategic business moves shaping the landscape. Let's delve into these developments, starting with some key insights from oncology. In the realm of oncology, minimal residual disease (MRD) is becoming increasingly pivotal. Tumor-informed MRD is being leveraged to... | 4m 51s | ||||||
| 6/18/26 | Eli Lilly's $65B M&A Surge & FDA's Drug Import Approval | Pharma and Biotech Daily | Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a rapidly evolving landscape marked by significant scientific breakthroughs, regulatory shifts, and strategic business maneuvers. The pharmaceutical and biotech sectors are buzzing with renewed vigor, as evidenced by an impressive resurgence in mergers and acquisitions. A recent analysis by PwC reports that M&A activity has reached over... | 5m 19s | ||||||
| 6/17/26 | Intellia's 89% Success in Phase 3 CRISPR Trial | Pharma and Biotech Daily | Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and strategic maneuvers transforming the industry landscape. Intellia Therapeutics has made remarkable progress with lonvoguran ziclumeran, achieving an 89% reduction in attack rates in its Phase 3 trial for hereditary angioedema. This gene therapy utilizes CRISPR technology combined with antisense oligon... | 3m 54s | ||||||
| 6/15/26 | Novartis' $23M RNA Breakthrough & Tavneos FDA Battle | Pharma and Biotech Daily | Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore a series of pivotal advancements and challenges shaping the industry landscape—ranging from scientific breakthroughs to regulatory maneuvers, all underscoring the sector's dynamic evolution. Novartis has made headlines with its investigational drug, Delpacibart Braxlosiran, which successfully met primary endpoints in a Phase 1/2 trial for t... | 5m 19s | ||||||
| 6/12/26 | Takeda's Zasocitinib Beats Sotyktu in Phase 3 Trial | Pharma and Biotech Daily✨ | drug developmentclinical trials+3 | — | ZasocitinibSotyktu+2 | — | TakedaZasocitinib+5 | — | 5m 03s | |
| 6/11/26 | Pfizer CEO Rethinks Germany Investments Amid Reform Concerns | Pharma and Biotech Daily✨ | PfizerGermany investments+3 | — | Pfizer | Germany | PfizerAlbert Bourla+5 | — | 4m 58s | |
| 6/10/26 | Merck & Gilead's HIV Pill Breakthrough: Phase 3 Success! | Pharma and Biotech Daily✨ | HIV treatmentpharmaceutical advancements+3 | — | HIV PillMerck & Co.+1 | — | HIVMerck+5 | — | 5m 23s | |
| 6/9/26 | Eli Lilly's Retatrutide Breakthrough: 30.3% Weight Loss Success | Pharma and Biotech Daily✨ | obesity treatmentdrug development+3 | — | retatrutideEli Lilly | — | Eli Lillyretatrutide+5 | — | 4m 35s | |
| 6/8/26 | Pfizer & Chai AI Breakthrough: $1.675B Gilead Deal | Pharma and Biotech Daily✨ | pharmaceutical advancementsbiotech collaboration+3 | — | PfizerChai Discovery+1 | — | PfizerChai Discovery+5 | — | 4m 31s | |
| 6/5/26 | Eli Lilly & Boehringer Cut $1B+ Investments in Germany | Pharma and Biotech Daily✨ | pharmaceutical investmentsbiotechnology+3 | — | Eli LillyBoehringer Ingelheim | Germany | Eli LillyBoehringer Ingelheim+5 | — | 5m 11s | |
| 6/4/26 | Legend Biotech's CAR T-Cell Breakthrough: 100% Response Rate | Pharma and Biotech Daily✨ | CAR T-Cell therapyclinical trials+3 | — | LB2501Legend Biotech | — | Legend BiotechCAR T-Cell+5 | — | 5m 50s | |
| 6/3/26 | Moderna-Merck Combo Cuts Melanoma Risk by 49% | Pharma and Biotech Daily✨ | cancer treatmentdrug development+3 | — | Intismeran AutogeneKeytruda+2 | — | ModernaMerck+6 | — | 5m 15s | |
| 6/2/26 | Akeso's Ivonescimab Shows 34% Death Risk Cut at ASCO | Pharma and Biotech Daily✨ | pharmaceutical advancementsbiotech developments+3 | — | ivonescimabAkeso+1 | — | Akesoivonescimab+5 | — | 5m 26s | |
| 6/1/26 | Pfizer's $10B Innovent Deal Boosts Cancer Drugs | Pharma and Biotech Daily✨ | PfizerInnovent Biologics+5 | — | PfizerInnovent Biologics | oncology sector | PfizerInnovent Biologics+4 | — | 5m 20s | |
| 5/29/26 | Eli Lilly's Zepbound Coverage Restored! Breaking News | Pharma and Biotech Daily✨ | Eli LillyZepbound+3 | — | ZepboundEli Lilly | — | Eli LillyZepbound+5 | — | 5m 43s | |
| 5/28/26 | Outlook Therapeutics Wins FDA Appeal for $1.3B Deal | Pharma and Biotech Daily✨ | FDA Appealpharmaceutical developments+4 | — | LytenavaOutlook Therapeutics | — | Outlook TherapeuticsLytenava+6 | — | 5m 18s | |
| 5/27/26 | Gilead's Hepcludex FDA Approval Marks Milestone | Pharma and Biotech Daily✨ | FDA approvalhepatitis D+3 | — | HepcludexGilead Sciences+1 | United States | GileadHepcludex+5 | — | 6m 13s | |
| 5/26/26 | Lilly's Obesity Drug Rivals Surgery: FDA Changes Ahead | Pharma and Biotech Daily✨ | obesity drugFDA changes+3 | — | Lilly's Obesity DrugFDA | — | Lillyobesity drug+5 | — | 4m 19s | |
| 5/25/26 | AstraZeneca's Datroway FDA Approved for TNBC | Pharma and Biotech Daily✨ | FDA approvaltriple-negative breast cancer+3 | — | DatrowayAstraZeneca+1 | triple-negative breast cancer | AstraZenecaDatroway+4 | — | 5m 47s | |
| 5/22/26 | Eli Lilly's $1B Novo Nordisk Deal: Diabetes Focus | Pharma and Biotech Daily✨ | Eli LillyNovo Nordisk+5 | — | Eli LillyNovo Nordisk+1 | Boston | Eli LillyNovo Nordisk+5 | — | 4m 43s | |
| 5/21/26 | Pfizer Leads Pneumococcal Vaccine Efforts | Pharma and Biotech Daily✨ | pneumococcal vaccinePfizer+3 | — | PfizerPharma Daily | — | Pfizerpneumococcal vaccine+3 | — | 5m 18s | |
| 5/20/26 | Takeda Faces $885M Verdict in Antitrust Case | Pharma and Biotech Daily✨ | antitrustlegal developments+3 | — | Takeda | — | Takedaantitrust case+4 | — | 5m 22s | |
Showing 25 of 62
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Similar Audience Demographics
Podcasts that attract a similar listener profile
Chart Positions
31 placements across 31 markets.
Chart Positions
31 placements across 31 markets.